文献速递妇产影像外周血管US

妊娠36周眼动脉多普勒预测子痫前期:既往模型的验证与更新

Ophthalmic artery Doppler at 36 weeks' gestation in prediction of pre-eclampsia: validation and update of previous model.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-01-12

这项前瞻性验证研究在6746例单胎妊娠35+0至36+6周筛查中验证并更新了结合母体眼动脉收缩期峰值流速比值的子痫前期预测模型,联合母体因素、MAP、UtA-PI、PlGF、sFlt-1和PSV比值在10%假阳性率下对3周内子痫前期预测检出率为85.0%,对任何时间子痫前期为65.7%。

要点

  • 孕35-37周眼动脉PSV比值联合母体因素及MAP、UtA-PI、PlGF、sFlt-1可有效预测子痫前期。
  • 10%假阳性率下,联合模型对3周内子痫前期检出率85.0%(95%CI 76.5-91.4%)。
  • 同一模型对评估后任何时间子痫前期检出率65.7%(95%CI 59.2-71.7%)。

核心结论

  • 孕35-37周母体眼动脉PSV比值联合其他生物标志物可有效预测后续子痫前期发生。

研究设计与样本

  • 前瞻性验证研究,验证数据集6746例单胎妊娠,训练数据集2287例,采用竞争风险模型,参考标准为2019年美国妇产科医师学会子痫前期诊断标准。

诊断标准与关键数值

  • 联合母体因素、MAP、UtA-PI、PlGF、sFlt-1和PSV比值在10%假阳性率下,3周内子痫前期检出率85.0%(95%CI 76.5-91.4%),任何时间子痫前期检出率65.7%(95%CI 59.2-71.7%)。

临床应用与阅片要点

  • 生物物理联合检测(母体因素、MAP、UtA-PI和PSV比值)优于低PlGF浓度(<第10百分位)或高sFlt-1/PlGF浓度比值(>第90百分位)筛查,但与母体因素联合PlGF和sFlt-1的生物化学检测在3周内和任何时间子痫前期预测上无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To validate and extend a model incorporating maternal ophthalmic artery Doppler at 35-37 weeks' gestation in the prediction of subsequent development of pre-eclampsia (PE).

METHODS: This was a prospective validation study of screening for PE (defined according to the 2019 American College of Obstetricians and Gynecologists criteria) by maternal ophthalmic artery peak systolic velocity (PSV) ratio in 6746 singleton pregnancies undergoing routine care at 35 + 0 to 36 + 6 weeks' gestation (validation dataset). Additionally, the data from the validation dataset were combined with those of 2287 pregnancies that were previously used for development of the model (training dataset), and the combined data were used to update the original model parameters. The competing-risks model was used to estimate the individual patient-specific risk of delivery with PE at any time and within 3 weeks from assessment by a combination of maternal demographic characteristics and medical history with PSV ratio alone and in combination with the established PE biomarkers of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1). We evaluated the predictive performance of the model by examining, first, the ability to discriminate between the PE and non-PE groups using the area under the receiver-operating-characteristics curve and the detection rate (DR) at fixed screen-positive (SPR) and false-positive rates of 10% and, second, calibration by measuring the calibration slope and calibration-in-the-large. McNemar's test was used to compare the performance of screening by a biophysical test (maternal factors, MAP, UtA-PI and PSV ratio) vs a biochemical test (maternal factors, PlGF and sFlt-1), low PlGF concentration (< 10th percentile) or high sFlt-1/PlGF concentration ratio (> 90th percentile).

RESULTS: In the validation dataset, the performance of screening by maternal factors and PSV ratio for delivery with PE within 3 weeks and at any time after assessment was consistent with that in the training dataset, and there was good agreement between the predicted and observed incidence of PE. In the combined data from the training and validation datasets, good prediction for PE was achieved in screening by a combination of maternal factors, MAP, UtA-PI, PlGF, sFlt-1 and PSV ratio, with a DR, at a 10% SPR, of 85.0% (95% CI, 76.5-91.4%) for delivery with PE within 3 weeks and 65.7% (95% CI, 59.2-71.7%) for delivery with PE at any time after assessment. The performance of a biophysical test was superior to that of screening by low PlGF concentration or high sFlt-1/PlGF concentration ratio but not significantly different from the performance of a biochemical test combining maternal factors with PlGF and sFlt-1 for both PE within 3 weeks and PE at any time after assessment.

CONCLUSION: Maternal ophthalmic artery PSV ratio at 35-37 weeks' gestation in combination with other biomarkers provides effective prediction of subsequent development of PE. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mansukhani T, Wright A, Arechvo A, et al. Ophthalmic artery Doppler at 36 weeks' gestation in prediction of pre-eclampsia: validation and update of previous model. Ultrasound Obstet Gynecol. 2024. PMID: 37616530. doi:10.1002/uog.27464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。